We show that for patients with FLT3-ITD-positive AML in CR1, a defined course of up to 12 months of maintenance therapy with midostaurin was safely added to SOC after recovery from alloHSCT and improved RFS at 18 months after alloHSCT by 13% (over SOC alone). This evidence concerns the gene FLT3 and acute myeloid leukemia.